Nádia Miléo Garcês de Couto

Nádia Miléo Garcês de Couto

Auto-generated profile, based on publicly available information

Nádia Miléo Garcês de Couto

Post-Graduation of Pharmaceutical Science Program, Faculty of Farmacy, Federal University of Rio Grande do Sul, Porto Alegre 90610-000, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LML.A.L. Maués
L.A.L. Maués
GAG.M. Alves
G.M. Alves
NCN.M.G. Couto
N.M.G. Couto
BSB.J.M. da Silva
B.J.M. da Silva
MAM.S.P. Arruda
M.S.P. Arruda
JNJosé Luiz Martins Do Nascimento
José Luiz Martins Do Nascimento
Glioblastoma, which is highly invasive and has a poor patient prognosis, is the most common type of brain tumor. Flavonoids have known antiproliferative and antineoplastic effects, such as apoptosis induction and tumor growth inhibition. We investigated the effects of treatment with three flavonoids (BAS-1, BAS-4, and BAS-6) isolated from the Amazon plant Brosimum acutifolium on the proliferation and migration of the C6 glioma cell line. Cytotoxicity was evaluated by MTT assay, and morphological changes were evaluated by phase-contrast microscopy and by transmission electron microscopy. Apoptosis was determined using Annexin V-FITC-propidium iodide (PI) staining. A hemolysis assay was used to evaluate plasma membrane injury. Antiproliferative effects were assessed by wound migration and colony formation assays. Mitochondrial transmembrane potential (ΔΨm) was determined using JC-1 dye and flow cytometry. To identify the flavonoid targets, western blotting was performed. BAS-1 and BAS-4 reduced C6 cell proliferation in a dose-dependent manner. BAS-6 showed no effect. Due to its high toxicity toward primary glial cells and its high hemolytic index, BAS-1 was not used in the remaining experiments. BAS-4 treatment did not induce cytotoxicity in primary glial cells; however, in glioma cells, it suppressed migration and invasion and led to apoptosis through mitochondrial damage, ΔΨm loss, cell cycle arrest, and reduced AKT phosphorylation, which is a component of the main cell survival pathway. We conclude that BAS-4 showed potential activity against glioma by inducing apoptosis mediated by ΔΨm loss and AKT pathway disruption, and future studies should further evaluate BAS-4 as a promising antineoplastic agent against glioblastoma.

13 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JWJulia Biz Willig
Julia Biz Willig
NCNádia Miléo Garcês de Couto
Nádia Miléo Garcês de Couto
DVDébora Renz Barreto Vianna
Débora Renz Barreto Vianna
CMCamila da Silveira Mariot
Camila da Silveira Mariot
SGSimone Gnoatto
Simone Gnoatto
DPDiogo André Pilger
Diogo André Pilger
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the formation of the BCR-ABL (breakpoint cluster region-Abelson) oncoprotein. As many patients display therapeutic resistance, the development of new drugs based on semisynthetic products represents a new potential therapeutic approach for treating the disease. In this study, we investigated the cytotoxic activity, possible mechanism of action of a hybrid compound of betulinic acid (BA) and brosimine B in CML cell lines that are sensitive (K-562) and resistant (K-562R) to imatinib, in addition to evaluating lower doses of imatinib in combination with the hybrid compound. The effects of the compound, and its combination with imatinib, on apoptosis, cell cycle, autophagy and oxidative stress were determined. The compound was cytotoxic in K-562 (23.57 ± 2.87 μM) and K-562R (25.80 ± 3.21 μM) cells, and a synergistic effect was observed when it was associated with imatinib. Apoptosis was mediated by the caspase 3 and 9 intrinsic pathway, and cell cycle evaluation showed arrest at G0/G1. In addition, the hybrid compound increased the production of reactive oxygen species and induced autophagy by increasing LC3II and Beclin-1 mRNA levels. Results suggest that this hybrid compound causes the death of both imatinib-sensitive and -resistant cell lines and may hold potential as a new anticancer treatment against CML.

1 January 2013 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
PBPatrícia M. S. S. Barros
Patrícia M. S. S. Barros
NCNádia M. G. de Couto
Nádia M. G. de Couto
ASAndressa S. B. Silva
Andressa S. B. Silva
Wagner Luiz Ramos BarbosaWagner Luiz Ramos Barbosa
Wagner Luiz Ramos Barbosa
For the registration of phytomedicines and their availability to the population, National Agency of Sanitary Surveillance (ANVISA) establishes quality, security, and efficacy parameters, stipulating control requirements similar to those applied to synthetic medicines. This work reports the investigation of the bark of Himatanthus lancifolius and its extracts aiming to contribute to the standardization of derivatives of this plant species. The developed quantification method shows high selectivity at 281nm, which confers confidence to the detection of the alkaloids. The method is robust, according to the current regulation, and shows linearity, precision, and accuracy, beside accessibility and simplicity in execute. The pH 10 alkaloid fraction obtained from the aqueous extract of the analyzed sample represents 0.219% in the dried extract. These results contribute for reducing the lack of methods for the quality control of phytomedicines prepared from H. lancifolius.